Charts

News

27 Mar, 2024
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
23 Mar, 2024
The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. ( NASDAQ:SPRB ), with the analysts...
21 Mar, 2024
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ: SPRB). Investors who purchased Spruce securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SPRB.
16 Mar, 2024
Spruce Biosciences, Inc. ( NASDAQ:SPRB ) investors will be delighted, with the company turning in some strong numbers...
14 Mar, 2024
Spruce Biosciences Inc(NASDAQ:SPRB) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 ...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded ...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter ...
Gainers Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. The company's market cap stands ...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded ...
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anheuser-Busch stock is falling on Thursday following news that 10% holder Altria is selling a portion of its stake in BUD shares. The post Is Altria Giving Up on Anheuser-Busch (BUD) Stock? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Wednesday,Spruce Biosciences Inc(NASDAQ:SPRB) released topline results from its CAHmelia-203 Phase 2b study of tildacerfont ...
Gainers Aptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fisker stock is falling hard on Thursday as FSR investors react to reports that the EV company is preparing to file for bankruptcy. The post Why Is Fisker (FSR) Stock Down 41% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spruce Biosciences stock is falling hard on Thursday as investors in SPRB shares react to the latest clinical trial data reported. The post Why Is Spruce Biosciences (SPRB) Stock Down 78% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
13 Mar, 2024
Strategic Cost Reductions Extend Cash Runway Through 2025 Despite Clinical Challenges
Gainers Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH.
13 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
30 Jan, 2024
Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.
22 Jan, 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).
05 Jan, 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).
04 Jan, 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for advancing tildacerfont for the treatment of adult and pediatric classic congenital adrenal hyperplasia (CAH).
20 Nov, 2023
Analysts have provided the following ratings for Spruce Biosciences (NASDAQ:SPRB) within the last quarter: Bullish Somewhat ...
13 Nov, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
02 Nov, 2023
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
20 Oct, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum ...
18 Oct, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipated milestones.
08 Sep, 2023
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement ...
Upgrades Wells Fargo upgraded the previous rating for TC Energy Corp (NYSE:TRP) from Underweight to Equal-Weight. TC Energy earned $0.71 ...
Over the past 3 months, 6 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically ...
Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. AGBA ...
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst ...
28 Aug, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.
16 Aug, 2023
15:00
FinancialContent
Spruce Biosciences (NASDAQ:SPRB) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...
14 Aug, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.
24 Jul, 2023
Spruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
23 Jun, 2023
17:04
Seeking Alpha
12 Jun, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105th Annual Meeting of the Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH).
25 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company’s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors.
24 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET.
22 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, was honored by the CARES Foundation, Inc. for its ongoing development of tildacerfont for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation is the only U.S.-based nonprofit organization solely dedicated to improving the lives of the CAH patient community and seeks to advance quality health care. Spruce Biosciences’ Chief Executive Officer, Javier Szwarcberg, M.D., M.P.H., accepted the Corporate Partner Award at the 15th Annual Everyone CARES Gala held in New York City on May 20.
16 May, 2023
Within the last quarter, Spruce Biosciences (NASDAQ:SPRB) has observed the following analyst ratings: Bullish Somewhat ...
15 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.
04 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2023 Annual Meeting taking place May 5-8, 2023, in San Diego, Calif. Mitchell Geffner, M.D., will present findings on a retrospective analysis of completion rates for adult and pediatric congenital adrenal hyperplasia (CAH) studies.
02 May, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.
23 Mar, 2023
Over the past 3 months, 4 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically ...
Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber ...
16 Mar, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.
28 Feb, 2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 2:40 PM ET.
11 Nov, 2022
10 Aug, 2022
05 Jan, 2022
14:09
Seeking Alpha
16 Nov, 2021
15 Nov, 2021
10 Aug, 2021

Related Articles